Well of course novice.....you know there is always a reason with me.
Want to see if the revenues in Q 3 jump 100%+ from the revenues last year or just the 45-55% they have been this year.
Q1 2018 $3,179,235
Q1 2019 $4,905,772 up 54% year over year
Q2 2018 $3,920,566
Q2 2019 $5,764,899 up 47%
Q3 2018 $3,832,935
Q3 2019 My guess and only my guess $7,841,132 up 105% or more, I could be crazy, been accused of it before but actually I think I am being conservative, we shall see I am also look for year over year revenues to end up being up 100% even though the first half of 2019 are only up 51%.
No one has been attention to the numbers which is all I ever look at because that long term and for the real growth in a share price is all that matters.
I mean it blows my damn minds, EPS dropping revenues up 51% YoY looking to be up 100% on the year. In 2020 with Zimhi next year they should be up IMHO and MHO only I think they will be up 200-500% in 2020 over 2019.
Yet people screaming about Adamis management etc who has zero to do with the marketing, selling, contracts, lobbying of state and local governments when it comes to Symjepi and soon to be Zimhi.
I mean you have a company Novartis a $52 billion a year company in control of all of the above and people just toss that aside and yawn? Okay, oh brilliant minds of the chart trading world, thanks for the long term $$. Do as you please short term I will be banking my 300-500% gains soon enough as I can think beyond the tip of my nose.
I like when they go up stay up and continue go up Q after Q year after year, like an investment should. Usually I don't give a toss about revenue estimates especially when it comes to biotech's, but, when you show me the money, you show me the $$ growling and a clear path that it will keep growing, well then, I'm your Huckleberry.
Peace out.
